In cohort 1 of this study, we used an attenuated schedule of neoadjuvant ipilimumab and
nivolumab. This cohort has now fully enrolled, and all eligible patients had resection of the
bladder <12 weeks from 1st cycle (23/24, 96%). In the current multicenter extension (cohort
2), n=30 patients will be randomized between two neoadjuvant treatment schemes, both based
upon an attenuated schedule of neoadjuvant ipilimumab and nivolumab.